SCIENTIFIC PROGRAM


MELANOMA BRIDGE 2015
Hotel Excelsior, Naples, Italy
Sala Partenope
December 1-4, 2015



December 1st 2015
Satellite Symposium "Surgery Bridge" **
Chairpersons: Nicola Mozzillo, Carlo Riccardo Rossi
2:00 PM Claus Garbe Lecture: Should Complete Lymphadenectomy be Performed in Patients with Positive Sentinel Nodes?
2:30 PM Andrea Maurichi Superficial and deep groin dissection in SN era
2:50 PM Corrado Caracò Radiophrequency nodal dissection
3:10 PM Antonio Sommariva Videoassisted superficial and deep groin dissection
3:30 PM Ester Simeone Nodal recurrence: surgery or adjuvant therapy
3:50 PM Nicola Mozzillo Electrochemotherapy
4:10 PM Carlo Riccardo Rossi Discussion
4:30 PM End of Symposium

Opening Ceremony: What’s new for melanoma patients and experts in 2015 **
Chairpersons: Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo
5:00 PM Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo Welcome and introduction
5:30 PM Francesco M. Marincola Award Lecture of Fondazione Melanoma
The quest toward the identification of the genetic determinants of cancer immune responsiveness

Patients meet the experts **
Chairpersons: Francesco de Lorenzo, Giuseppe Palmieri
6:00 PM Roundtable “What’s new for melanoma patients and experts in 2015”
Francesco de Lorenzo, European Cancer Patient Coalition
Alberto Cerretti, AIMaMe - Associazione Italiana Malati di Melanoma
Valerie Guild, AIM at Melanoma
Gianni Altavilla, Associazione contro il melanoma
Chiara Puri Purini, MelanomaItalia
Sabrina Nardi, Cittadinanzattiva
Antonio Brancaccio, Elisabetta Colangelo, Fondazione Melanoma Onlus
7:30 PM Welcome Cocktail

Patients association meeting **
Organized by AIMaMe - Associazione Italiana Malati di Melanoma
Chairpersons: Francesco de Lorenzo, Sara Vigna
7:30 PM AIMaMe incontra i clinici
Paolo A. Ascierto, Nicola Mozzillo, Giuseppe Palmieri
AIMaMe incontra le associazioni e le fondazioni impegnate nella lotta al melanoma
Valerie Guild, AIM at Melanoma
Chiara Puri Purini, MelanomaItalia
Antonio Brancaccio, Elisabetta Colangelo, Fondazione Melanoma Onlus


December 2st 2015
Molecular and Immuno advances
Chair: Gerardo Botti, Ena Wang
9:00 AM Michael Davies Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma
9:25 AM Michael Krauthammer Insights from Sequencing the Melanoma Exome
9:50 AM Roger Lo Genomic, epigenomic and immune evolution of melanoma acquiring resistance to MAPK-targeted therapies
10:15 AM Gennaro Ciliberto Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance
10:40 AM Break
10:55 AM Stefani Spranger Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance
11:20 AM Cassian Yee Endogenous T Cell Therapy: The Next Generation of Personalized Adoptive Cellular Therapy
12:45 PM Soldano Ferrone Grp94 and BRAF inhibitor resistance
12:10 PM Gerardo Botti, Ena Wang Discussion on the best abstracts submitted on Molecular and Immuno advances
Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs
12:25 Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Adriana Esposito, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo A. Ascierto, Giuseppina Liguori, Gerardo Botti Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma
12:40 Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo A. Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur Vemurafenib in Patients With BRAFV600 Mutation–Positive Metastatic Melanoma: Final Overall Survival Results of the BRIM-3 Study
12:55 Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma
1:10 PM Lunch

Assemblea Generale di AIMaMe
12:00 AM Sara Vigna, Francesco de Lorenzo

Approvazione del bilancio preventivo e del programma delle attività 2016
Elezione del Consiglio Direttivo
Indicazione di esperti per la nomina del Comitato Scientifico
Relazione del Presidente sull’attività svolta e sul bilancio provvisorio
Il contributo di FAVO
14:30 PM Chiusura dell'assemblea

Combination Therapies
Chair: Paolo A. Ascierto, Claus Garbe
2:10 PM Sandra Demaria Harnessing radiotherapy to improve responses to immunotherapy in cancer
2:35 PM Samir Khleif New Strategies in Combination Immune Therapy
3:00 PM Yang Xin Fu Targeting tumor tissue to increase innate sensing for immunotherapy
3:25 PM Reinhard Dummer Biomarkers for treatment decision?
3:50 PM Break
4:05 PM Igor Puzanov Combining oncolytic therapies in the era of checkpoint inhibitors
4:30 PM Michael Postow Immune checkpoint blockade for melanoma: Should we combine or sequence ipilimumab and PD-1 antibody therapy?
4:55 PM Nicola Mozzillo Surgery as a therapeutic option in metastatic stage IV melanoma
5:20 PM Paolo A. Ascierto, Claus Garbe Discussion on the best abstracts submitted on Combination Therapies
Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts)
5:35 PM F. Stephen Hodi, Geoff Gibney, Ryan Sullivan, Jeffrey A. Sosman, Craig L. Slingluff, Jr, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh Nair, Leslie Fecher, Elizabeth Buchbinder, Mary Ruisi, George Kong, Christine Horak, Jeffrey S. Weber An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) (CheckMate 064)
5:50 PM James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, David Hogg, Andrew Hill, Matteo S. Carlino, Pascal Wolter, Celeste Lebbé, Jacob Schachter, Luc Thomas, Jessica C. Hassel, Paul Lorigan, Dana Walker, Joel Jiang, F. Stephen Hodi, Jedd D. Wolchok Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
6:05 PM Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma
6:20 PM Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma
6:35 PM Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma
6:50 PM Paolo A. Ascierto, Francesco M. Marincola, N. Mozzillo Conclusions


December 3rd 2015
News on Immunotherapy
Chair: Michele Maio, Giuseppe Palmieri
8:45 AM Michele Maio, Giuseppe Palmieri Discussion on the best abstracts submitted on News in Immunotherapy
8:45 AM Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067
9:00 AM Ahmad Tarhini An update on adjuvant and neoadjuvant therapy for melanoma
9:25 AM Sanjiv Agarwala Overview of intralesional oncolytic therapy
9:50 AM Alexander Eggermont Update on adjuvant ipilimumab EORTC18071, update on ongoing adjuvant pembrolizumab EORTC1325 trials
Sponsored Symposium ** - PD-1 Immunotherpay: New Paradigms in the Treatment of Melanoma and Beyond
10:15 AM Paolo A. Ascierto Welcome and Introduction
10:25 AM Thomas F. Gajewski Immunotherapy: Changing the Treatment Landscape of Melanoma
10:50 AM Paolo A. Ascierto Cancer Immunotherapy in the Future: Learnings from Melanoma
11:10 AM Paolo A. Ascierto, Thomas F. Gajewski Questions and answers
Sponsored by MSD
11:15 AM Break
11:30 AM Hassane Zarour Targeting multiple inhibitory pathways in melanoma
11:55 AM Howard Kaufman An Update on Oncolytic Virus Immunotherapy for the Treatment of Melanoma
12:20 PM David Stroncek Improving Adoptive Immune Therapy using Genetically Engineered T cells
12:45 PM Michele Maio, Giuseppe Palmieri Discussion on the best abstracts submitted on News in Immunotherapy
Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066
1:00 PM James Larkin, Sandra P. D’Angelo, Jeffrey A. Sosman, Celeste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, F. Stephen Hodi, Paul Lorigan, Kerry J. Savage, Wilson Miller, Peter Mohr, Ivan Marquez-Rodas, Julie Charles, Martin Kaatz, Mario Sznol, Jeffrey S. Weber, Alexander N. Shoushtari, Mary Ruisi, Joel Jiang, Jedd D. Wolchok Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma (MEL)
1:15 PM Lunch

Tumor Microenvironment and Biomarkers
Chair: Giuseppe Masucci, Alessandro Testori
2:15 PM Alessandra Cesano Biomarker development for Immuno-Oncology and Cancer ImmunoTherapy: Simultaneous Digital Counting of Nucleic-Acids and Proteins at 800-plex
2:40 PM Thomas Gajewski Tumor and host factors mediating resistance to immunotherapy
3:05 PM Janis M. Taube Multiparameter pathologic assessment of the PD-1/PD-L1 pathway in melanoma
3:30 PM Jennifer A. Wargo Understanding immune and molecular determinants of response to melanoma therapy
3:55 PM Break
4:10 AM Bernard A. Fox Developing Cancer Immunotherapy Strategies that Change the Tumor Microenvironment and Eliminate Cancer
4:35 PM Licia Rivoltini Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression?
5:00 PM Magdalena Thurin Update on the SITC Biomarker Taskforce: progress and challenges
5:25 PM Laurence Zitvogel Predictors of response to immune checkpoint blockade in metastatic melanoma
5:50 PM Giuseppe Masucci, Alessandro Testori Discussion on the best abstracts submitted on Tumor Microenvironment and Biomarkers
Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma
6:05 PM Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab
6:20 PM Anna Passarelli, Marco Tucci, Stefania Stucci, Francesco Mannavola, Mariaelena Capone, Gabriele Madonna, Paolo A. Ascierto, Franco Silvestris Franco Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients
6:35 PM María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel Immunological prognostic factors in stage III melanomas
6:50 PM Paolo A. Ascierto, Francesco M. Marincola, N. Mozzillo Conclusions


December 4th 2015
World-Wide Immunoscore Task Force: an Update
Chair: Paolo A. Ascierto, Francesco M. Marincola, Jerome Galon
9:30 AM Jerome Galon Immunoscore in the era of cancer immunotherapy
9:50 AM Paolo A. Ascierto Immunoscore and immunoprofiling in melanoma
10:10 AM Tilman Rau The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology
10:30 AM Break
10:45 AM Carlo Bifulco Next generation immunoprofiling
11:05 AM Giuseppe Masucci In search of personalized cancer immunotherapy
11:25 AM Franck Pages The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients
11:45 AM Roundtable “World-Wide Immunoscore Task Force”
12:30 PM Conclusions
12:45 PM Lunch


Economic Sustainability of melanoma treatments: Regulatory, Health Technology Assessment and Market Access issues
Chair: Paolo A. Ascierto, Pier Luigi Canonico
2:00 PM Jorge Camarero (EMA) Nivolumab, the regulatory experience in immunotherapy
2:20 PM Paolo Foggi (AIFA) The point of view of the Italian Medicines Agency (AIFA)
2:40 PM Deborah Morrison (NICE) The point of view of the National Institute for Health and Care Excellence (NICE)
3:00 PM Break
3:20 PM Francesco Perrone Financial toxicity: an emerging problem
3:40 PM Claudio Jommi Evidence to optimize access for melanoma drugs
4:00 PM Francesco de Lorenzo, Valerie Guild The point of view of the patient associations
4:40 PM Paolo A. Ascierto, Pier Luigi Canonico Roundtable on the economic sustainability of melanoma treatments
Jorge Camarero, European Medicines Agency
Francesco de Lorenzo, European Cancer Patient Coalition
Paolo Foggi, Italian Medicines Agency
Valerie Guild, AIM at Melanoma
Claudio Jommi, University of Piemonte Orientale
Deborah Morrison, National Institute for Health and Care Excellence
Giuseppe Palmieri, Italian Melanoma Intergroup
Francesco Perrone, Italian Association of Medical Oncology
5:25 PM Paolo A. Ascierto, Pier Luigi Canonico Conclusions




POSTER SESSIONS



Molecular and immuno-advances
Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto and Emilia Caputo Human Melanoma Cells Resistant to B-RAF and MEK inhibition Exhibit Mesenchymal-like Features
Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors
Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino and Angela Ianaro Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression
Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld, Miklos Kasler Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma.
Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma
Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad HuR positively regulates migration of HTB63 melanoma cells
Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook Prolyl 4-(C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy
Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero Urokinase receptor antagonists: novel agents for the treatment of melanoma
Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells
Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida New insights in mitochondrial metabolic reprogramming in melanoma
Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle

Combination therapies
Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile Angela Gismondi, Angela Santoni, Paola Nisticò Chemoimmunotherapy elicits polyfunctional anti-tumor CD8+ T cells depending on the activation of an AKT pathway sustained by ICOS
Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients
Gianluca Di Monta, Corrado Caracò, Massimiliano Di Marzo, Ugo Marone, Maria Luisa Di Cecilia, Nicola Mozzillo Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study

News in Immunotherapy
Francesco Sabbatino, Celeste Fusciello, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection
Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Immunotherapy and hypophysitis: a case report

Tumor Microenvironment and biomakers
Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential.
Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca Utility of simultaneous measurement of three serum tumor markers in melanoma patients
Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca The significance of various cut-off levels of Melanoma Inhibitory Activity in evaluation of cutaneous melanoma patients
Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile The long noncoding RNA hotair is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease

Other
Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection
Valeria De Biasio, Vincenzo C. Battarra Epidemiological survey on related psychopathology in melanoma




IMMUNOTHERAPY BRIDGE
Hotel Excelsior, Naples, Italy
Sala Partenope
December 5, 2015



Immunotherapy beyond melanoma
Chair: Alfredo Budillon, Graham Pawelec
9:15 AM Silvia Formenti Predictor of response to Radiation and Immunotherapy
9:40 AM Pedro Romero Cancer vaccines revisited
10:05 AM Graham Pawelec Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer
10:30 AM Rolf Kiessling Checkpoint blockade in the treatment of melanoma and neuroblastoma; effect on T cell activation and MDSCs
10:55 AM Break
11:10 AM Maria Libera Ascierto Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment
11:35 AM Ignacio Melero Understanding and combining CD137-targeted immunotherapy
12:00 PM Sacha Gnjatic Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients
12:25 PM Speiser Daniel Anti-cancer immunity despite T cell “exhaustion"
12:50 PM Lunch

Immunotherapy in oncology (I-O): data from clinical trial
Chair: Filippo de Braud, Cesare Gridelli
1:50 PM Paolo A. Ascierto What we learned from Immunotherapy in the past years
2:15 PM Vera Hirsh The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
2:40 PM Hans Joerg Hammers Immune checkpoint inhibition in kidney cancer
3:05 PM Break
3:20 PM Rita Nanda Immunotherapy for Breast Cancer
3:45 PM Antonio Pinto Immunotherapy for Hemato-Oncology
4:10 PM Sandro Pignata Immunotherapy in ovarian cancer
4:35 PM Discussion
5:20 PM Conclusions



* To be confirmed
** Not included in the CME accredited program


Download full programs: Melanoma Bridge 2015 Scientific, Surgery Bridge 2015, Immunotherapy Bridge 2105

For information please contact info@melanomabridge.org